David Meek steps back from Mirati as Krazati struggles to compete

10 August 2023

San Diego, USA-based cancer specialist Mirati Therapeutics (Nasdaq: MRTX) is to replace its chief executive, David Meek, with former CEO Charles Baum taking over on an interim basis.

The announcement comes several months after the firm announced the late-stage failure of the SAPPHIRE study, with development of the kinase blocker sitravatinib subsequently being discontinued.

On the plus side, during his tenure Mr Meek succeeded in launching Krazati (adagrasib) for certain people with lung cancer, after the US regulator granted Accelerated Approval for the KRAS inhibitor at the end of last year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK